Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E15.71 EPS (ttm)9.45 Insider Own0.20% Shs Outstand751.22M Perf Week-0.67%
Market Cap111.50B Forward P/E12.21 EPS next Y12.15 Insider Trans-3.43% Shs Float750.35M Perf Month-5.31%
Income7.22B PEG1.88 EPS next Q2.74 Inst Own81.30% Short Float0.96% Perf Quarter-0.06%
Sales22.16B P/S5.03 EPS this Y35.20% Inst Trans-0.68% Short Ratio2.55 Perf Half Y-6.98%
Book/sh38.09 P/B3.90 EPS next Y9.16% ROA10.00% Target Price185.31 Perf Year0.20%
Cash/sh46.24 P/C3.21 EPS next 5Y8.37% ROE25.70% 52W Range127.70 - 177.64 Perf YTD-7.33%
Dividend4.00 P/FCF17.77 EPS past 5Y13.60% ROI12.50% 52W High-15.52% Beta0.85
Dividend %2.70% Quick Ratio4.70 Sales past 5Y7.60% Gross Margin81.00% 52W Low17.52% ATR2.93
Employees17900 Current Ratio5.00 Sales Q/Q9.80% Oper. Margin39.90% RSI (14)44.79 Volatility1.95% 1.61%
OptionableYes Debt/Eq1.20 EPS Q/Q18.50% Profit Margin32.60% Rel Volume1.08 Prev Close148.42
ShortableYes LT Debt/Eq1.12 EarningsJul 28 AMC Payout35.30% Avg Volume2.83M Price150.07
Recom2.40 SMA20-2.15% SMA50-3.02% SMA200-1.09% Volume2,834,528 Change1.11%
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Jun-29-16 03:24PM  Three Biotech GiantsBut Only Two are Worth Buying at Barrons.com
02:24PM  Behind the Recent Fall in BioMarins Premium Valuation
02:06PM  Why Did Alexion Fall after Brexit?
01:15PM  Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" at Motley Fool
01:00PM  These Stocks Are Strong July Performers (AMGN, BPL) at Investopedia
12:12PM  Long-term Brexit Fallout May Take a Toll on These Healthcare Stocks
06:08AM  Coverage initiated on Amgen by Bernstein
Jun-28-16 12:01PM  5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero at 24/7 Wall St.
10:55AM  Biotechs: After Brexit, Buy the Stocks and Get the Pipelines For Free at Barrons.com
10:13AM  Credit Suisse Sees 'Reasons For Optimism' On AbbVie at Barrons.com
09:40AM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
06:05AM  Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley
Jun-27-16 09:42PM  The Largest Drug Pipelines Will Surprise You
02:06PM  Alexion Pharmaceuticals: Brexit Be Damned; Citigroup Ups to Buy Citing "Dark Sky Valuation" at Barrons.com
10:29AM  Is Brexit Good for Biotech? Maybe at Barrons.com
07:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
07:01AM  Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Jun-24-16 01:53PM  Biotech: Buy the Brexit Blowup? at Barrons.com
11:15AM  3 Biotech Stocks to Buy in the Wake of the Brexit Vote at Motley Fool
11:08AM  Amgen Fits Into Pfizer's Restructuring Plans Perfectly
09:56AM  Brexit means little for biotech stocks, analyst says at MarketWatch
Jun-23-16 10:41AM  The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016 at Motley Fool
10:36AM  Why Biotechnology Goliath Amgen Is a Solid Long-Term Investment
Jun-22-16 06:00PM  Amgen Sponsors QB3@953 Incubator For Life Science Startups PR Newswire
04:57PM  Medicare 'Death Panel' Is On Ice; Biotechs Rally
10:50AM  Biotech: Why Take the Risk? at Barrons.com
Jun-21-16 06:14PM  This Is the Most Important Business Trend in Pharma at Fortune
04:43PM  Why Biotech is Getting Crushed at Barrons.com
Jun-20-16 07:17AM  Amgen Is Looking Vulnerable to a Deep Selloff
Jun-18-16 09:41AM  2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't at Motley Fool
Jun-17-16 04:00PM  Amgen Appoints Esteban Santos Executive Vice President, Operations PR Newswire
Jun-15-16 04:46PM  Relypsa Sales Numbers Surprise to the Upside
02:51PM  AbbVie: Low Expectations, Cheap Valuation, What's Not to Love? at Barrons.com
Jun-14-16 04:55PM  AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
01:07PM  Amgen CEO: Volatile climate impacts deals
11:01AM  Regeneron: Nine Reasons Praluent Could Be Forced From the US Market at Barrons.com
10:59AM  Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Jun-13-16 04:00PM  Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab PR Newswire
01:03PM  Tricking the Common Cold Into Destroying Cancer at Motley Fool
07:30AM  [$$] Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants at The Wall Street Journal
Jun-12-16 05:25PM  Insiders See Huge Upside In These Biotechs
05:21AM  Behind Expedias headquarters move at MarketWatch
Jun-10-16 06:42PM  5 Appealing Biotechnology Stocks for Healthy Long-term Returns
04:00PM  New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression PR Newswire
11:58AM  These 6 Drugmakers Could Be The Next Price War Casualties
09:17AM  AMGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers PR Newswire
08:12AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : June 10, 2016
08:10AM  Short Sellers Become More Selective on Major Biotechs at 24/7 Wall St.
02:30AM  BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Jun-09-16 08:17PM  UPDATE: Biotech Stocks: Much Ado About Nothing at ASCO? at Barrons.com
06:22PM  Novartis (NVS) Announces Positive Results on Migraine Drug
01:36PM  Are stocks too expensive?
Jun-08-16 05:25PM  Good news, migraine sufferers! Amgen just posted positive data for its drug at CNBC
04:48PM  Amgen says migraine prevention drug meets main goal of study
04:30PM  Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine PR Newswire
02:38PM  Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
12:19PM  AbbVie Stock Downgraded As Worlds Best-Selling Drug Faces Rivals
11:33AM  Biotech Stocks: Wait Until Next Year at Barrons.com
Jun-07-16 09:00AM  New National Survey Sheds Light On How To Better Engage Students In Science Education PR Newswire
Jun-06-16 07:00PM  Hunting growth, Samsung races to get up to speed on biosimilar drugs
04:00PM  New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen PR Newswire
09:44AM  Better Dividend Stock: Pfizer vs. Amgen at Motley Fool
Jun-05-16 11:49AM  How Mylan Is Taking On One of the Worlds Top Breast Cancer Drugs at Fortune
Jun-04-16 11:41AM  The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit) at Motley Fool
Jun-03-16 04:15PM  Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers PR Newswire
04:00PM  Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference PR Newswire
02:18PM  Biotech: What's the Trade? at Barrons.com
10:10AM  Stock Market News for June 03, 2016
Jun-01-16 11:54AM  Where The Big Short Is Finding Value
02:30AM  Bayer Collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) to Investigate Stivarga® (Regorafenib) Tablets as Additional Adjuvant Therapy in Colon Cancer PR Newswire
May-31-16 06:46PM  How to Discover the Best Biotechs in the World
01:36PM  Summer good for stocks?
08:16AM  Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval
May-28-16 08:07AM  3 Growth Stocks to Buy in June at Motley Fool
12:01AM  [$$] Amgen's Autumn Gems at Barrons.com
May-27-16 12:09PM  Amgen Gets CHMP's Positive Opinion To Extend Indication Of Kyprolis For Relapsed Multiple Myeloma Treatment
10:01AM  Interested in Medivation? Take a Number! at Motley Fool
07:21AM  Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma PR Newswire
May-26-16 04:00PM  Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" PR Newswire
10:34AM  Please Gilead, Celgene and Amgen. Don't Buy Medivation. at Barrons.com
08:06AM  Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : May 26, 2016
06:10AM  AMGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-25-16 07:08PM  Amgen Announces Early Tender Results Of Senior Notes Exchange Offers PR Newswire
04:59PM  Medivation: Three Biotech Giants Enter. Which One Leaves? at Barrons.com
04:08PM  Amgen Announces Pricing Terms Of Senior Notes Exchange Offers PR Newswire
11:32AM  Sanofi Moves To Replace Medivations Board As New Buyers Rumored
08:20AM  Short Sellers Grow More Selective on Major Biotechs at 24/7 Wall St.
May-24-16 08:25AM  Billionaires Lightened Their Load on These 3 Widely-Held Stocks in Q1 at Motley Fool
May-23-16 12:25PM  Biotech: The Next Pricing Controversy? at Barrons.com
05:55AM  A Rudderless Market
May-21-16 11:06AM  Struggling Novartis heart drug boosted by new medical guidelines Reuters
May-20-16 06:05AM  AMGEN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
May-19-16 06:24PM  Gambling debt, stock tip lead to $1 mln settlement but no charges for Mickelson Reuters
06:02PM  Amgen Announces Voting Results of Annual Meeting of Stockholders PR Newswire
04:34PM  Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association PR Newswire
12:52PM  Heart attack gene?
12:05PM  Can Amgens Prolia Continue Its Strong Growth Trajectory in 2016?
11:55AM  This Medical Breakthrough Could Drastically Reduce Heart Attacks at Fortune
May-18-16 05:14PM  [$$] Amgen Researchers Find Gene Associated With Lower Risk of Heart Disease at The Wall Street Journal
Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM